Latent autoimmune diabetes in adults (LADA) is a unique form of diabetes that shares features with both type 1 and type 2 diabetes, making proper treatment essential for preserving the body’s remaining ability to produce insulin and preventing long-term complications.

Understanding How LADA Is Managed

When someone receives a diagnosis of latent autoimmune diabetes in adults, the main goal of treatment is to control blood sugar levels while protecting the pancreas cells that still produce insulin. Unlike typical type 1 diabetes, where insulin production stops quickly, LADA progresses more slowly. This slower progression means that treatment approaches need to be carefully tailored to each person’s current stage of the condition.^[1]

The treatment strategy for LADA depends heavily on how much insulin the pancreas is still able to make. Doctors measure this using a blood test called C-peptide, which shows how active the insulin-producing cells remain. Based on these levels and other factors like blood sugar control and the presence of autoantibodies, healthcare providers develop treatment plans that may change over time as the disease progresses.^[9]

Because LADA is often misdiagnosed as type 2 diabetes at first, many patients initially receive treatments meant for type 2. However, as the autoimmune process continues to damage the pancreas, these treatments become less effective. Recognizing this and adjusting treatment early can make a significant difference in outcomes and quality of life.^[3]

The treatment journey for LADA typically involves lifestyle modifications combined with medications, eventually progressing to insulin therapy. The timing and choice of treatments are crucial because the right approach may help preserve remaining pancreas function for longer periods, though this is still being studied in research settings.^[4]

Standard Treatment Approaches

In the early stages of LADA, when the pancreas still produces a reasonable amount of insulin, doctors often recommend lifestyle changes as the foundation of treatment. These include maintaining a healthy weight through balanced nutrition, engaging in regular physical activity, and managing other health factors. For people who are overweight, weight loss can improve how the body responds to whatever insulin is still being produced.^[14]

Oral medications play an important role in managing LADA, particularly in the beginning. Metformin is commonly prescribed as it helps the body use insulin more effectively by reducing insulin resistance in muscles, fat, and the liver. This medication has been used safely for many years and may be continued even after insulin therapy begins. Metformin works by decreasing the amount of sugar the liver releases into the bloodstream and improving how body tissues respond to insulin.^[16]

Thiazolidinediones, such as pioglitazone and rosiglitazone, are another class of insulin-sensitizing medications that may be used in LADA. These drugs work similarly to metformin by making the body’s tissues more responsive to insulin. However, they come with potential side effects including weight gain, fluid retention, and an increased risk of bone fractures, which must be weighed against their benefits.^[16]

Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), including medications like linagliptin, saxagliptin, and sitagliptin, have shown promise in managing LADA. These drugs work by increasing the body’s own production of hormones that stimulate insulin release when blood sugar rises. They are generally well-tolerated and may help improve blood sugar control in people with LADA, though more extensive research is needed to determine if they can help preserve insulin-producing cell function over time.^[16]

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as dulaglutide, liraglutide, and semaglutide, represent another treatment option. These injectable medications mimic a natural hormone that stimulates insulin release, slows digestion, and reduces appetite. Early studies, including the AWARD trial, have shown that these medications can effectively lower blood sugar in people with LADA, producing results comparable to those seen in type 2 diabetes. However, their effectiveness decreases when C-peptide levels become very low, indicating minimal remaining insulin production.^[16]

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), including canagliflozin, dapagliflozin, and empagliflozin, work by causing the kidneys to remove excess sugar through urine. While these medications have shown potential benefits in LADA, there is an important safety concern. People with LADA, especially those with lower C-peptide levels or who are not overweight, may have an increased risk of developing diabetic ketoacidosis, a dangerous condition where the body breaks down fat too quickly, producing harmful acids in the blood. This risk must be carefully considered before prescribing SGLT2 inhibitors to LADA patients.^[16]

As LADA progresses and the pancreas loses its ability to produce sufficient insulin, insulin therapy becomes necessary. Unlike oral medications that depend on the pancreas having some function, insulin directly replaces what the body can no longer make. Most experts agree that insulin should be started sooner rather than later in LADA, possibly within the first year after diagnosis. Early insulin therapy may help protect remaining insulin-producing cells from further damage, improve blood sugar control, and reduce the autoimmune attack on the pancreas, though these benefits are still being investigated.^[9]

The timing for starting insulin varies from person to person, but typically becomes necessary within one to five years after diagnosis. Doctors monitor C-peptide levels regularly—usually every six months—to determine the right time to begin insulin. When C-peptide falls below certain thresholds, it signals that the pancreas can no longer produce enough insulin on its own, making insulin therapy essential.^[9]

Insulin treatment for LADA is generally safe and effective. The type and dosing of insulin must be individualized based on blood sugar patterns, lifestyle, diet, and other factors. Most people with LADA eventually require a regimen similar to type 1 diabetes, which may include multiple daily injections or use of an insulin pump. The goal is to mimic the body’s natural insulin patterns as closely as possible throughout the day and night.^[2]

Treatment Being Studied in Clinical Trials

Research into new treatments for LADA remains limited compared to type 1 and type 2 diabetes, but several promising approaches are being explored. Since LADA shares characteristics with both types of diabetes, researchers are investigating whether treatments proven effective for type 1 or type 2 diabetes might also benefit people with LADA, and whether unique therapies targeting the specific features of LADA can be developed.^[4]

Clinical trials have examined whether starting insulin therapy very early—even before it becomes strictly necessary—might help preserve pancreas function longer. The theory is that by providing insulin from outside sources, the remaining insulin-producing cells might be given a chance to rest and recover, potentially slowing the autoimmune attack. Some studies suggest that early insulin intervention improves metabolic control, supports continued insulin secretion, and may modify the autoimmune response against the pancreatic cells. However, these findings need confirmation through larger, more comprehensive studies before becoming standard practice.^[16]

Researchers are also investigating newer diabetes medications to see if they offer advantages specifically for LADA. GLP-1 receptor agonists are being studied more extensively because they showed promising results in initial trials. These medications not only help control blood sugar but may also have protective effects on the insulin-producing cells. Scientists want to determine whether these drugs can slow the progression of LADA and delay the need for insulin therapy.^[16]

DPP-4 inhibitors are another focus of ongoing research. While they are already used in clinical practice for LADA, larger randomized controlled trials are needed to definitively establish whether they can preserve insulin secretion over time. These studies are examining both the glucose-lowering effects and potential disease-modifying properties of this drug class.^[16]

Some research is exploring whether immunomodulating therapies—treatments that adjust the immune system’s activity—might benefit people with LADA. Since LADA is caused by an autoimmune process where the immune system mistakenly attacks insulin-producing cells, therapies that calm this immune response could theoretically slow or stop disease progression. However, this area of research is still in very early stages for LADA specifically, and no immunomodulating treatments are currently recommended outside of research studies.^[9]

Clinical trials are being conducted in various locations around the world, including countries in Europe, the United States, and Asia. Eligibility for these trials typically depends on factors such as recent diagnosis, presence of specific autoantibodies (particularly GAD antibodies), age at onset, and current C-peptide levels. People interested in participating in LADA research can discuss options with their healthcare providers or search clinical trial registries.^[15]

One challenge in LADA research is that the condition is highly variable from person to person. Some individuals have characteristics closer to type 1 diabetes with rapid loss of pancreas function, while others have features more similar to type 2 diabetes with slower progression and some insulin resistance. This variability means that researchers need to study different subgroups of LADA patients separately, which requires larger study populations and more complex trial designs.^[4]

Future research directions include investigating whether specific genetic or immunologic markers can predict which LADA patients will progress more quickly, allowing for more personalized treatment approaches. Scientists are also interested in understanding whether lifestyle interventions, such as specific dietary patterns or exercise regimens, might influence disease progression in LADA, similar to their proven benefits in type 2 diabetes.^[2]

Most common treatment methods

• Lifestyle modifications
  • Regular physical activity to improve insulin sensitivity and blood sugar control
  • Healthy eating patterns with balanced nutrition to manage blood glucose levels
  • Weight management, particularly for individuals who are overweight or obese
  • Smoking cessation to reduce overall health risks and improve treatment outcomes
• Insulin sensitizers
  • Metformin to reduce insulin resistance and liver glucose production
  • Thiazolidinediones (pioglitazone, rosiglitazone) to increase tissue sensitivity to insulin, though with consideration of side effects including weight gain and bone fracture risk
• Incretin-based therapies
  • DPP-4 inhibitors (linagliptin, saxagliptin, sitagliptin) that are generally well-tolerated and may improve glycemic control
  • GLP-1 receptor agonists (dulaglutide, liraglutide, semaglutide) that have shown beneficial results in improving metabolic control in LADA patients with adequate remaining insulin production
• SGLT2 inhibitors
  • Medications like canagliflozin, dapagliflozin, and empagliflozin that reduce glucose reabsorption in the kidneys
  • Used cautiously due to increased ketoacidosis risk in patients with low C-peptide levels or lower body weight
• Insulin therapy
  • Multiple daily injection regimens to replace insufficient endogenous insulin production
  • Early initiation potentially within the first year after diagnosis to preserve beta-cell function
  • Individualized dosing based on blood sugar patterns, diet, and lifestyle factors
  • May include use of insulin pumps for more precise insulin delivery
• Monitoring and testing
  • Regular C-peptide measurements, typically every six months, to assess remaining pancreatic function
  • Blood glucose monitoring to guide treatment adjustments
  • Assessment of autoantibodies (particularly GAD antibodies) for diagnosis and monitoring